Drug updated on 5/8/2024
| Dosage Form | Injection (intravenous; 350 mg/7 mL [50 mg/mL]) |
| Drug Class | EGF receptor-directed and MET receptor-directed antibody |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.
- Indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rybrevant (amivantamab-vmjw) Prescribing Information. | 2024 | Janssen Biotech, Inc., Horsham, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations. | 2023 | Journal of Oncology Pharmacy Practice |
| Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes. | 2022 | Current Medical Research and Opinion |